Skip to main content

Opterion Health secures investment of 6.5 million Swiss francs

| News

Opterion Health secures investment of 6.5 million Swiss francs


Opterion Health has raised a total of 6.5 million Swiss francs as part of a financing round. The company, which is headquartered in Muttenz in the canton of Basel-Landschaft, won over investors with its innovative peritoneal dialysis solution. Preparations are now underway for the start of a Phase I clinical trial.

Opterion Health AG has now closed a financing round that was oversubscribed by 60 percent. According to a press release, the company managed to successfully secure investment totaling 6.5 million Swiss francs. As part of the financing round, additional option capital in the amount of 7.3 million Swiss francs was also issued. Both existing and new private and institutional investors participated in the financing round.

Opterion Health is developing a solution for an innovative peritoneal dialysis (PD) solution. According to information from the company itself, the solution is set to “revolutionize” the dialysis market by replacing the gold standard of the current market leader. At present, the solution is still in the preclinical phase. However, the fresh capital should now help to accelerate the process so that a Phase I clinical trial can begin sooner than originally expected.

Settlement supported by Basel Area Business & Innovation

In addition to closing the financing round, Opterion Health has also announced a change in personnel. In this context, Stefan Wohlfeil has resigned his seat on the Board of Directors in order to enter retirement. Shareholders have now elected Jan-Anders Karlsson and Robert Leitz as new members of the Board of Directors. The two newcomers will bring many years of experience in the areas of life sciences and finance to the company.

In 2021, Opterion Health moved its headquarters to Muttenz in the canton of Basel-Landschaft, with the aim of exploiting the region’s life sciences ecosystem. In so doing, the company was supported by the investment and innovation promotion agency Basel Area Business & Innovation.

Share this article

Sign up to receive our newsletter in your inbox.

You may also be interested in

The power of a persuasive pitch deck

Are you an entrepreneur striving to secure investment for your biotech startup? Start with an effective pitch deck to catch...
Read More

Roche investing an additional 1.2 billion Swiss francs in Basel

Roche will be putting an additional 1.2 billion Swiss francs towards the renovation of its site in Basel. This investment...
Read More

Nouscom secures 67.5 million euros in financing

Biotech company Nouscom has raised 67.5 million euros in a series C financing round. The Basel-based firm intends to use...
Read More

Celebrating six months of innovation: i4Challenge accelerator New Ideas 2022/2023

On the 5th of July 2023, the 3rd iteration of the i4Challenge accelerator program New Ideas came to its conclusion....
Read More

How open innovation in healthtech hubs is fueling the rise of digital healthcare

How the ever-increasing uptake of digital solutions is enhancing patient engagement, increasing access to care and lowering the cost of...
Read More

How to access the U.S. market with your medical device

In one of our latest Venture Mentoring events by Basel Are Business & Innovation, we invited Nila-Pia Rähle to speak...
Read More

Do you have a question? We'd like to hear from you.